A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

351

Participants

Timeline

Start Date

October 14, 2022

Primary Completion Date

February 26, 2027

Study Completion Date

February 26, 2027

Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be administered.

DRUG

Dostarlimab

Dostarlimab will be administered

DRUG

Belrestotug

Belrestotug will be administered.

DRUG

Nelistotug

Nelistotug will be administered.

Trial Locations (101)

1414

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

1602

GSK Investigational Site, Florida

2193

GSK Investigational Site, Parktown

2650

GSK Investigational Site, Wilrijk

2800

GSK Investigational Site, Tatabánya

3000

GSK Investigational Site, Santa Fe

3200

GSK Investigational Site, Gyöngyös

7570

GSK Investigational Site, Cape Town

7600

GSK Investigational Site, Mar del Plata

10210

GSK Investigational Site, Bangkok

11528

GSK Investigational Site, Athens

12120

GSK Investigational Site, Pathum Thani

12462

GSK Investigational Site, Haidari - Athens

13009

GSK Investigational Site, Marseille

13125

GSK Investigational Site, Berlin

14033

GSK Investigational Site, Caen

16132

GSK Investigational Site, Genova

20520

GSK Investigational Site, Turku

21565

GSK Investigational Site, Incheon

22927

GSK Investigational Site, Großhansdorf

24125

GSK Investigational Site, Bergamo

26506

GSK Investigational Site, Morgantown

28027

GSK Investigational Site, Madrid

GSK Investigational Site, PamplonaNavarra

28041

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

28223

GSK Investigational Site, Pozuelo de AlarcOn Madr

29010

GSK Investigational Site, Málaga

29107

GSK Investigational Site, Quimper

33076

GSK Investigational Site, Bordeaux

33322

GSK Investigational Site, Plantation

33520

GSK Investigational Site, Tampere

34214

GSK Investigational Site, Istanbul

35016

GSK Investigational Site, Las Palmas de Gran Canar

37045

GSK Investigational Site, Verona

37404

GSK Investigational Site, Chattanooga

40002

GSK Investigational Site, Khon Kaen

41110

GSK Investigational Site, Larissa

44280

GSK Investigational Site, Guadalajara

45147

GSK Investigational Site, Essen

46009

GSK Investigational Site, Valencia

46026

GSK Investigational Site, Valencia

50134

GSK Investigational Site, Florence

50200

GSK Investigational Site, Chiang Mai

51900

GSK Investigational Site, Abu Dhabi

54645

GSK Investigational Site, Thessaloniki

55200

GSK Investigational Site, Samsun

57001

GSK Investigational Site, Pylaia Thessaloniki

57010

GSK Investigational Site, Thessaloniki

57124

GSK Investigational Site, Pisa

65130

GSK Investigational Site, Vaasa

67091

GSK Investigational Site, Strasbourg

69126

GSK Investigational Site, Heidelberg

78209

GSK Investigational Site, San Luis Potosí City

83100

GSK Investigational Site, Avellino

87131

GSK Investigational Site, Albuquerque

90029

GSK Investigational Site, Oulu

90110

GSK Investigational Site, Kho Hong Hat Yai

C1426ABP

GSK Investigational Site, Buenos Aires

R8324CVE

GSK Investigational Site, Cipoletti Rio Negro

C1426AGE

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

J5402DIL

GSK Investigational Site, San Juan

14784-400

GSK Investigational Site, Barretos

90610-000

GSK Investigational Site, Porto Alegre

01246-000

GSK Investigational Site, São Paulo

29043-260

GSK Investigational Site, Vitória

07747

GSK Investigational Site, Jena

115 27

GSK Investigational Site, PapagosAthens

H-1121

GSK Investigational Site, Budapest

277-8577

GSK Investigational Site, Chiba

812-8582

GSK Investigational Site, Fukuoka

673-8558

GSK Investigational Site, Hyōgo

241-8515

GSK Investigational Site, Kanagawa

589-8511

GSK Investigational Site, Osaka

350-1298

GSK Investigational Site, Saitama

7512 KZ

GSK Investigational Site, Enschede

9728 NZ

GSK Investigational Site, Groningen

8934 AD

GSK Investigational Site, Leeuwarden

3543 AZ

GSK Investigational Site, Utrecht

20-954

GSK Investigational Site, Lublin

82-550

GSK Investigational Site, Prabuty

08-110

GSK Investigational Site, Siedlce

4434-502

GSK Investigational Site, Gaia

4835-044

GSK Investigational Site, Guimarães

1500-650

GSK Investigational Site, Lisbon

1998-018

GSK Investigational Site, Lisbon

4200-072

GSK Investigational Site, Porto

03080

GSK Investigational Site, Seoul

03722

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon Gyeonggi-do

06080

GSK Investigational Site, Badajoz

08916

GSK Investigational Site, Badalona

08035

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

06680

GSK Investigational Site, Ankara

06800

GSK Investigational Site, Ankara

07070

GSK Investigational Site, Antalya

Unknown

GSK Investigational Site, Abu Dhabi

TS4 3BW

GSK Investigational Site, Middlesbrough

HA6 2RN

GSK Investigational Site, Middlesex

WV10 0QP

GSK Investigational Site, Wolverhampton

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

iTeos Therapeutics

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY